Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis

Frontiers in Medicine

article

Zepei Feng¹  Jinwei Zhang²  Weilong Tan³  Chunhui Wang³  Qiong Chen³  Chao Shen¹  Haozhi Fan⁴  Yun Zhang¹  Peng Huang¹  Ming Yue⁵ 

[1] Department of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University;Department of Anesthesiology, Affiliated Drum Tower Hospital of Medical College of Nanjing University;Institute of Epidemiology and Microbiology, Eastern Theater Command Centers for Disease Prevention and Control;Department of Information, First Affiliated Hospital of Nanjing Medical University;Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University

关键词: antiviral agents;    HCV-viremia;    Hepatitis C;    kidney donors;    kidney transplant;    meta-analysis;   

DOI  :  10.3389/fmed.2022.802686

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Background: With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to negative recipients. Methods Multiple databases were searched for a systematic and comprehensive up to March 2022. The primary outcomes included the percentage of sustained virological response at week 12 after the end of treatment (SVR12), adverse events (AEs; any grade), and severe adverse events (SAEs) as the endpoints. Publication bias was examined by using the funnel plots and Egger's test. Results In total, 16 studies with 454 subjects were included in the study and the pooled estimate of SVR12, AEs, and SAEs rates were 100.0% (95% CI: 99.2-100.0), 1.9%(95%CI: 0.0-4.9), and 0.0% (95%CI: 0.0-1.5). Subgroup analysis showed that pooled SVR12 rates were 100.0% (95%CI: 99.6-100.0) for genotype (GT)1a and 96.3% (95%CI: 83.3-100.0) for GT2; 100.0% (95%CI: 98.9-100.0) for DAAs treatments; and 100.0% (95%CI: 98.2-100.0) for prophylaxis subgroup. Egger's tests showed that no publication bias was found in this study. Conclusion This comprehensive analysis showed the high efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to HCV-negative recipients.

【 授权许可】

CC BY